Details of Drug-Drug Interaction
| Drug General Information (ID: DDIB6SX5VH) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Levamlodipine | Drug Info | Edetate calcium disodium anhydrous | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antihypertensives Agent | Chelating Agents | |||||||
| Structure | |||||||||
| Mechanism of Levamlodipine-Edetate calcium disodium anhydrous Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of antihypertensive agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Levamlodipine | Edetate calcium disodium anhydrous | |||||||
| Mechanism |
Calcium channel blocker Voltage-gated L-type calcium channel Blocker |
Decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium Calcium-containing products |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Voltage-dependent L-type calcium channel subunit beta-1 |
×
Structure
Sequence
MVQKTSMSRGPYPPSQEIPMEVFDPSPQGKYSKRKGRFKRSDGSTSSDTTSNSFVRQGSAESYTSRPSDSDVSLEEDREALRKEAERQALAQLEKAKTKPVAFAVRTNVGYNPSPGDEVPVQGVAITFEPKDFLHIKEKYNNDWWIGRLVKEGCEVGFIPSPVKLDSLRLLQEQKLRQNRLGSSKSGDNSSSSLGDVVTGTRRPTPPASAKQKQKSTEHVPPYDVVPSMRPIILVGPSLKGYEVTDMMQKALFDFLKHRFDGRISITRVTADISLAKRSVLNNPSKHIIIERSNTRSSLAEVQSEIERIFELARTLQLVALDADTINHPAQLSKTSLAPIIVYIKITSPKVLQRLIKSRGKSQSKHLNVQIAASEKLAQCPPEMFDIILDENQLEDACEHLAEYLEAYWKATHPPSSTPPNPLLNRTMATAALAASPAPVSNLQGPYLASGDQPLERATGEHASMHEYPGELGQPPGLYPSSHPPGRAGTLRALSRQDTFDADTPGSRNSAYTELGDSCVDMETDPSEGPGLGDPAGGGTPPARQGSWEDEEEDYEEELTDNRNRGRNKARYCAEGGGPVLGRNKNELEGWGRGVYIR
|
|||||||
| Gene Name | CACNB1 | ||||||||
| Uniprot ID | CACB1_HUMAN | ||||||||
| KEGG Pathway | hsa:782 | ||||||||
| Protein Family | Calcium channel beta subunit family | ||||||||
| Protein Function |
Regulatory subunit of L-type calcium channels (PubMed:1309651, PubMed:8107964, PubMed:15615847). Regulates the activity of L-type calcium channels that contain CACNA1A as pore-forming subunit (By similarity). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit and increases the presence of the channel complex at the cell membrane (PubMed:15615847). Required for functional expression L-type calcium channels that contain CACNA1D as pore-forming subunit (PubMed:1309651). Regulates the activity of L-type calcium channels that contain CACNA1B as pore-forming subunit (PubMed:8107964).
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products. | ||||||||